Reported 1 day ago
Teva Pharmaceutical Industries Limited has announced the FDA approval and U.S. launch of Generic Saxenda, the first generic GLP-1 medication for weight loss, aimed at addressing the increasing demand in the U.S. market. This product is designed for adults with obesity and adolescents aged 12-17 who are overweight. This launch marks Teva's fifth first-to-market generic entry this year, further establishing its robust generics portfolio.
Source: YAHOO